Spots Global Cancer Trial Database for Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC
Official Title: SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW MetaStatic Breast Cancer
Study ID: NCT06263543
Interventions
Study Description
Brief Summary: The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
Contact Details
Name: Reshma L Mahtani, D.O.
Affiliation: Miami Cancer Institute at Baptist Health, Inc.
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
